Full history for every metric is available with a Kvantra account
Pascal Biosciences Inc. (PSCBF)
Key financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | 0 | 0 | 0 | 0 | 1 | 1 |
| Operating profit | CAD m | -1 | -1 | |||||
| Net profit | CAD m | - | -3 | -1 | -1 | -0 | -0 | -0 |
| EPS reported | CAD | -0.02 | -0.01 | |||||
| Operating cashflow per share | CAD | -0.02 | -0.02 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.02 | -0.02 | |||||
| Free cash flow | CAD m | -0 | -0 | |||||
| Net debt | CAD m | 0 | 0 | |||||
| Book value equity | CAD m | 1 | 1 | |||||
| Book value per share | CAD | 0.06 | 0.02 | |||||
| Number of shares | m | 23.53 | 38.14 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.16 | 6.35 | |||||
| P/S LTM | x | 2.38 | 6.28 | |||||
| P/FCF LTM | x | -4.09 | -13.47 | |||||
| EV/EBITDA LTM | x | -2.36 | -9.29 | |||||
| EV/Sales LTM | x | 2.77 | 6.64 | |||||
| Earnings Yield LTM | % | -25.01% | -10.82% | |||||
| FCF Yield | % | -24.43% | -7.43% | |||||
| Quality | ||||||||
| ROE | % | -29.05% | -187.90% | |||||
| ROIC | % | -36.81% | -36.81% | |||||
| Operating margin | % | -133.68% | -133.68% | |||||
| Gross margin | % | -51.54% | -51.54% | |||||
| FCF/Sales | % | -58.15% | -58.15% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.57 | -0.87 | |||||
| Net Debt/EBITDA | x | -0.33 | -0.33 | |||||
| EBIT/Net interest | x | -31.11 | -31.11 | |||||
| Net debt/market cap | % | 16.56% | 5.68% | |||||
| Net debt/Equity | x | 0.19 | 0.36 | |||||
| Gross debt/equity | x | 0.50 | 0.54 | |||||
Company overview
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pascal Biosciences Inc. (PSCBF)
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free